Anupam Rasayan India Ltd (ANURAS) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Anupam Rasayan reported robust revenue growth of 89% YoY, reaching 491 crores in Q1 FY26.
- The company experienced strong performance in pharma and polymer segments, along with recovery in the agrochemical segment.
- Exports accounted for 58% of total revenue, with the USA and Japan markets showing encouraging trends.
- The company signed a long-term agreement with a Japanese conglomerate for supplying niche molecules used in semiconductors, data centers, and electronics.
- Anupam Rasayan also partnered with Elite Innovations (a subsidiary of Fuchs) to produce electrolyte solutions for energy storage in India.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.